Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"$357.0 million","upfrontCash":"Undisclosed","newsHeadline":"Leo Pharma Sells Portfolio of Four Products to Cheplapharm","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","amount":"$562.0 million","upfrontCash":"$562.0 million","newsHeadline":"Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Undisclosed","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"Astrazeneca's Atacand to be Divested to Cheplapharm in More than 70 Countries","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca's Atacand Divestment to Cheplapharm in More than 70 Countries Completed","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Cheplapharm Arzneimittel Gmbh","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$825.9 million","upfrontCash":"Undisclosed","newsHeadline":"Cheplapharm Places Notes in A Volume of \u20ac750m in Challenging Market Environment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"GERMANY","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Cheplapharm Arzneimittel Gmbh

    Menu

    Cheplapharm Arzneimittel Gmbh

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Cheplapharm Arzneimittel Gmbh

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Cheplapharm Places Notes in A Volume of €750m in Challenging Market Environment

              Details:

              The proceeds from the new bonds will be used to finance the acquisition of the worldwide commercial rights for Zyprexa (olanzapine), an antipsychotic medication, from Eli Lilly and Company.

              Lead Product(s): Olanzapine

              Therapeutic Area: Psychiatry/Psychology Product Name: Zyprexa

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $825.9 million Upfront Cash: Undisclosed

              Deal Type: Private Placement April 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cheplapharm Arzneimittel Gmbh

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AstraZeneca's Atacand Divestment to Cheplapharm in More than 70 Countries Completed

              Details:

              AstraZeneca has completed the divestment of commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in over 70 countries to Cheplapharm Arzneimittel GmbH (Cheplapharm).

              Lead Product(s): Candesartan Cilexetil

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atacand

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: AstraZeneca

              Deal Size: $400.0 million Upfront Cash: Undisclosed

              Deal Type: Divestment January 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cheplapharm Arzneimittel Gmbh

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Astrazeneca's Atacand to be Divested to Cheplapharm in More than 70 Countries

              Details:

              AstraZeneca would sell rights for its heart failure and blood pressure medicines Atacand and Atacand Plus to Germany’s Cheplapharm Arzneimittel GmbH. Agreement supports strategy of focusing on newer medicines in main therapy areas.

              Lead Product(s): Candesartan Cilexetil

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Atacand

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: AstraZeneca

              Deal Size: $400.0 million Upfront Cash: Undisclosed

              Deal Type: Divestment October 30, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cheplapharm Arzneimittel Gmbh

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD

              Details:

              The portfolio to be divested to Cheplapharm is comprised Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium.

              Lead Product(s): Undisclosed

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Undisclosed

              Recipient: Takeda Pharmaceutical

              Deal Size: $562.0 million Upfront Cash: $562.0 million

              Deal Type: Divestment September 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Cheplapharm Arzneimittel Gmbh

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Germany
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Leo Pharma Sells Portfolio of Four Products to Cheplapharm

              Details:

              The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha©, Locoid©, Pimafucin©, and Zineryt©.

              Lead Product(s): Alfacalcidol

              Therapeutic Area: Nephrology Product Name: One-Alpha

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Leo Pharma

              Deal Size: $357.0 million Upfront Cash: Undisclosed

              Deal Type: Divestment August 31, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY